- Home
- CZNC vs TNGX Comparison
CZNC vs TNGX Comparison
Compare CZNC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- TNGX
- Stock Information
- Founded
- CZNC 1864
- TNGX 2014
- Country
- CZNC United States
- TNGX United States
- Employees
- CZNC N/A
- TNGX N/A
- Industry
- CZNC Major Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- TNGX Health Care
- Exchange
- CZNC Nasdaq
- TNGX Nasdaq
- Market Cap
- CZNC 330.3M
- TNGX 317.4M
- IPO Year
- CZNC N/A
- TNGX N/A
- Fundamental
- Price
- CZNC $20.41
- TNGX $1.76
- Analyst Decision
- CZNC
- TNGX Strong Buy
- Analyst Count
- CZNC 0
- TNGX 7
- Target Price
- CZNC N/A
- TNGX $12.33
- AVG Volume (30 Days)
- CZNC 24.0K
- TNGX 801.9K
- Earning Date
- CZNC 05-06-2025
- TNGX 05-07-2025
- Dividend Yield
- CZNC 5.45%
- TNGX N/A
- EPS Growth
- CZNC 7.45
- TNGX N/A
- EPS
- CZNC 1.69
- TNGX N/A
- Revenue
- CZNC $106,129,000.00
- TNGX $42,069,000.00
- Revenue This Year
- CZNC $9.38
- TNGX N/A
- Revenue Next Year
- CZNC $3.77
- TNGX N/A
- P/E Ratio
- CZNC $12.12
- TNGX N/A
- Revenue Growth
- CZNC 1.43
- TNGX 15.17
- 52 Week Low
- CZNC $16.50
- TNGX $1.71
- 52 Week High
- CZNC $22.68
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- CZNC 47.96
- TNGX 33.97
- Support Level
- CZNC $19.58
- TNGX $1.80
- Resistance Level
- CZNC $20.98
- TNGX $2.04
- Average True Range (ATR)
- CZNC 0.48
- TNGX 0.18
- MACD
- CZNC 0.01
- TNGX 0.01
- Stochastic Oscillator
- CZNC 49.70
- TNGX 20.19
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.